Disease activity score-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis: data from the GUEPARD trial and ESPOIR cohort

Samankaltaisia teoksia

• GUEPARD treat-to-target strategy is significantly more efficacious than ESPOIR routine care in early rheumatoid arthritis according to patient-reported outcomes and physician global estimate
  Tekijä: Castrejón, Isabel, et al.
  Julkaistu: (2013)
• Diagnostic impact of routine Lyme serology in recent-onset arthritis: results from the ESPOIR cohort
  Tekijä: Guellec, Dewi, et al.
  Julkaistu: (2016)
• Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort
  Tekijä: Lukas, Cédric, et al.
  Julkaistu: (2019)
• The gap between practice and guidelines in the choice of first-line disease modifying antirheumatic drug in early rheumatoid arthritis: results from the ESPOIR cohort
  Tekijä: Benhamou, Mathilde, et al.
  Julkaistu: (2009)
• Defining cut-off values for disease activity states and improvement scores for patient-reported outcomes: the example of the Rheumatoid Arthritis Impact of Disease (RAID)
  Tekijä: Dougados, Maxime, et al.
  Julkaistu: (2012)